DCK antibody
(2 references)-
- Target See all DCK Antibodies
- DCK (Deoxycytidine Kinase (DCK))
-
Reactivity
- Human
-
Host
- Mouse
-
Clonality
- Monoclonal
-
Conjugate
- This DCK antibody is un-conjugated
-
Application
- Western Blotting (WB), Immunohistochemistry (IHC), Flow Cytometry (FACS)
- Characteristics
- Homo sapiens deoxycytidine kinase (DCK)
- Purification
- Purified from mouse ascites fluids by affinity chromatography
- Immunogen
- Full length human recombinant protein of human DCK (NP_000779) produced in HEK293T cell.
- Clone
- 16G6
- Isotype
- IgG1
- Top Product
- Discover our top product DCK Primary Antibody
-
anti-Deoxycytidine Kinase (DCK) antibody
KO Validated DCK Reactivity: Human WB, IHC, IF, IP, IHC (p), ICC Host: Rabbit Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) antibodyDCK Reactivity: Human WB, IHC, IF, IHC (p), FACS Host: Mouse Monoclonal 3F5 unconjugated
anti-Deoxycytidine Kinase (DCK) antibodyDCK Reactivity: Human WB, IHC, IHC (p), FACS Host: Mouse Monoclonal 16G6 unconjugated
anti-Deoxycytidine Kinase (DCK) (Center) antibodyDCK Reactivity: Human, Mouse, Rat WB, IF, IP, IHC (p), ICC Host: Rabbit Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 171-200), (C-Term) antibodyDCK Reactivity: Human, Mouse WB, IF, IP, IHC (p) Host: Rabbit Polyclonal RB05276 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 161-260) antibodyDCK Reactivity: Human WB, ELISA, IF Host: Mouse Monoclonal 1D12 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reactivity: Human WB, IHC, IF Host: Rabbit Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reactivity: Human WB, IP Host: Rabbit Polyclonal unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 161-260) antibodyDCK Reactivity: Human WB, ELISA, IF Host: Mouse Monoclonal 2F10 unconjugated
anti-Deoxycytidine Kinase (DCK) (AA 1-260) antibodyDCK Reactivity: Human WB, IF Host: Mouse Polyclonal unconjugated
-
- Application Notes
- WB 1:500~2000, IHC 1:150, FLOW 1:100,
- Comment
-
The concentration of the product may vary between diferrent lots.
- Restrictions
- For Research Use only
-
- Format
- Liquid
- Concentration
- 0.5-1.0 mg/mL
- Buffer
- PBS (PH 7.3) containing 1 % BSA, 50 % glycerol and 0.02 % sodium azide.
- Preservative
- Sodium azide
- Precaution of Use
- This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Storage
- -20 °C
-
-
: "Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity." in: BMC cancer, Vol. 18, Issue 1, pp. 466, (2018) (PubMed).
: "Prognostic effect of hENT1, dCK and HuR expression by morphological type in periampullary adenocarcinoma, including pancreatic cancer." in: Acta oncologica (Stockholm, Sweden), Vol. 55, Issue 3, pp. 286-96, (2016) (PubMed).
-
: "Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity." in: BMC cancer, Vol. 18, Issue 1, pp. 466, (2018) (PubMed).
-
- Target
- DCK (Deoxycytidine Kinase (DCK))
- Alternative Name
- DCK (DCK Products)
- Background
- Deoxycytidine kinase (DCK) is required for the phosphorylation of several deoxyribonucleosides and their nucleoside analogs. Deficiency of DCK is associated with resistance to antiviral and anticancer chemotherapeutic agents. Conversely, increased deoxycytidine kinase activity is associated with increased activation of these compounds to cytotoxic nucleoside triphosphate derivatives. DCK is clinically important because of its relationship to drug resistance and sensitivity.
- Molecular Weight
- 30.3 kDa
- Gene ID
- 1633
- NCBI Accession
- NM_000788
- HGNC
- 1633
-
